Breaking News, Collaborations & Alliances

Monte Rosa & Novartis Partner to Develop Immune-Mediated Disease Treatments

Monte Rosa to apply its QuEEN product engine for the discovery and development of degraders to be further developed and commercialized by Novartis.

Author Image

By: Charlie Sternberg

Associate Editor

Monte Rosa Therapeutics Inc., a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, has agreed to collaborate with Novartis to develop novel degraders for immune-mediated diseases. The agreement is the company’s second with Novartis, in addition to a global exclusive license agreement for Monte Rosa’s VAV1 degraders, including MRT-6160, announced in October 2024. Under the new agreement, Monte Rosa’s scientists will apply their proprietary A...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters